Cargando…

Systemic immunotoxin therapy of cancer: advances and prospects.

Detalles Bibliográficos
Autor principal:	Wawrzynczak, E. J.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1991
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977692/ https://www.ncbi.nlm.nih.gov/pubmed/1911210

Ejemplares similares

Refinement of an indirect immunotoxin assay of monoclonal antibodies recognising the human small cell lung cancer cluster 2 antigen.
por: Derbyshire, E. J., et al.
Publicado: (1993)

Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.
por: Wawrzynczak, E. J., et al.
Publicado: (1992)

Potent cytotoxic action of the immunotoxin SWA11-ricin A chain against human small cell lung cancer cell lines.
por: Derbyshire, E. J., et al.
Publicado: (1992)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

Selective cytotoxic activity of immunotoxins composed of a monoclonal anti-Thy 1.1 antibody and the ribosome-inactivating proteins bryodin and momordin.
por: Stirpe, F., et al.
Publicado: (1988)

Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.
por: Wawrzynczak, E. J., et al.
Publicado: (1990)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Clinical targeting recombinant immunotoxins for cancer therapy
por: Li, Meng, et al.
Publicado: (2017)

Antibody-Based Immunotoxins for Colorectal Cancer Therapy
por: Sanz, Laura, et al.
Publicado: (2021)

Simulation and Stability Assessment of Anti-EpCAM Immunotoxin for Cancer Therapy
por: Hosseinian, Seyed-Ali, et al.
Publicado: (2018)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

Immunotoxins and Other Conjugates Containing Saporin-S6 for Cancer Therapy
por: Polito, Letizia, et al.
Publicado: (2011)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect
por: Heiat, Mohammad, et al.
Publicado: (2021)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
por: Simon, Nathan, et al.
Publicado: (2016)

Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview
por: Polito, Letizia, et al.
Publicado: (2016)

Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy
por: Dieffenbach, Michael, et al.
Publicado: (2020)

Recombinant immunotoxins development for HER2-based targeted cancer therapies
por: Mahmoudi, Reza, et al.
Publicado: (2021)

GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer
por: Marszalowicz, Glen P., et al.
Publicado: (2014)

Immunotoxins: A Review of Their Use in Cancer Treatment
por: Aruna, G
Publicado: (2006)

Intratumoral anti-HuD immunotoxin therapy for small cell lung cancer and neuroblastoma
por: Ehrlich, Debra, et al.
Publicado: (2014)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

Immunotoxins: From Design to Clinical Application
por: Kreitman, Robert J., et al.
Publicado: (2021)

B7-1 (CD80) as target for immunotoxin therapy for Hodgkin's disease.
por: Vooijs, W. C., et al.
Publicado: (1997)

Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary
por: Tortorella, Lori L., et al.
Publicado: (2012)

Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer
por: Fleming, Bryan D., et al.
Publicado: (2016)

Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin
por: Flavell, D J, et al.
Publicado: (2001)

Toxin and Immunotoxin Based Therapeutic Approaches
por: Bortolotti, Massimo, et al.
Publicado: (2022)

Use of Ribosome-Inactivating Proteins from Sambucus for the Construction of Immunotoxins and Conjugates for Cancer Therapy
por: Ferreras, José M., et al.
Publicado: (2011)

Nanobody-Based EGFR-Targeting Immunotoxins for Colorectal Cancer Treatment
por: Narbona, Javier, et al.
Publicado: (2023)

Expression and Evaluation of HuscFv Antibody -PE40 Immunotoxin for Target Therapy of EGFR-Overexpressing Cancers
por: Falahatgar, Dianoush, et al.
Publicado: (2018)

Development of Recombinant Immunotoxins for Hairy Cell Leukemia
por: Kreitman, Robert J., et al.
Publicado: (2020)

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
por: Pegna, Guillaume Joe, et al.
Publicado: (2022)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
por: Flavell, D. J., et al.
Publicado: (1997)

Enhancement of immunotoxin activity using chemical and biological reagents.
por: Wu, M.
Publicado: (1997)

Abrin Immunotoxin: Targeted Cytotoxicity and Intracellular Trafficking Pathway
por: Gadadhar, Sudarshan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_410m7seqgudh5elhc5lbv6nctp